Guy A. Young, MD

Professor of Pediatrics (Clinical Scholar)

Image of Guy A. Young, MD
Is this your profile? Click to edit

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children’s Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children’s Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children’s Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

  • National Hemophilia Foundation: Physician of the Year, 2013

Research Funding

  • Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH · R01HL095110 · Sep 26, 2008 – Jan 31, 2013 · Role: Principal Investigator
  • FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH · R01FD003091 · Sep 20, 2006 – May 31, 2009 · Role: Principal Investigator

Publications

  • Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A. Blood. 2026 Oct 16.. View in PubMed
  • Successful Use of Sutimlimab in two Pediatric Patients With Refractory Cold Antibody-Mediated Autoimmune Hemolytic Anemia. Pediatr Blood Cancer. 2026 Oct 12.. View in PubMed
  • Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2026 Oct; 10(7):106954.. View in PubMed
  • Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study. Blood Adv. 2026 09 08; 10(17):6032-6042.. View in PubMed
  • Safety and efficacy of fondaparinux in pediatric venous thromboembolism: A retrospective cohort study. Thromb Res. 2026 Aug; 264:109798.. View in PubMed
  • T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers. Pediatr Blood Cancer. 2026 Sep; 73(9):e70518.. View in PubMed
  • Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors – 26-week results from FRONTIER. Blood Adv. 2026 Jul 17.. View in PubMed
  • Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents. Am J Hematol. 2026 Aug; 101(8):1781-1782.. View in PubMed
  • New Treatment in Haemophilia: Challenges, Controversies and Uncertainties. Haemophilia. 2026 Apr 16.. View in PubMed
  • Advances in Hemophilia: New Treatments and Complications in Laboratory Testing/Monitoring. Clin Lab Med. 2026 Jun; 46(2):167-183.. View in PubMed